BRPI0511261A - linhagem isolada de lactobacillus sp., uso de uma linhagem isolada de lactobacillus sp., e composição farmacêutica - Google Patents

linhagem isolada de lactobacillus sp., uso de uma linhagem isolada de lactobacillus sp., e composição farmacêutica

Info

Publication number
BRPI0511261A
BRPI0511261A BRPI0511261-3A BRPI0511261A BRPI0511261A BR PI0511261 A BRPI0511261 A BR PI0511261A BR PI0511261 A BRPI0511261 A BR PI0511261A BR PI0511261 A BRPI0511261 A BR PI0511261A
Authority
BR
Brazil
Prior art keywords
lactobacillus
strain
thymidine
isolated lactobacillus
pharmaceutical composition
Prior art date
Application number
BRPI0511261-3A
Other languages
English (en)
Inventor
Lothar Steidler
Sabine Neirynck
Original Assignee
Vib Vzw
Univ Gent
Univ Cork
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vib Vzw, Univ Gent, Univ Cork filed Critical Vib Vzw
Publication of BRPI0511261A publication Critical patent/BRPI0511261A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LINHAGEM ISOLADA DE LACTOBACILLUS SP., USO DE UMA LINHAGEM ISOLADA DE LACTOBACILLUS SP., E COMPOSIçãO FARMACêUTICA. A invenção está relacionada a uma linhagem Lactobacillus recombinante, com limitado crescimento e viabilidade no ambiente. Mais particularmente, ela está relacionada a um Lactobacillus recombinante que pode apenas sobreviver em um meio, onde timidina está presente. Por meio dessa estrita dependência da ação da timidina, a morte por falta da timidina é rapidamente induzida nessa linhagem recombinante. Uma modalidade preferida é um Lactobacillus que pode apenas sobreviver em um organismo hospedeiro, onde timidina está presente, mas não pode sobreviver fora do organismo hospedeiro em ausência desse composto meio. Além disso, a referida linhagem Lactobacillus pode ser transformada com moléculas profiláticas e/ou terapêuticas e pode, como tal, ser usada para tratar doenças tais como, mas não limitado a, doenças inflamatórias dos intestinos.
BRPI0511261-3A 2004-05-18 2005-05-18 linhagem isolada de lactobacillus sp., uso de uma linhagem isolada de lactobacillus sp., e composição farmacêutica BRPI0511261A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04102202 2004-05-18
PCT/EP2005/052296 WO2005111194A1 (en) 2004-05-18 2005-05-18 Self-containing lactobacillus strain

Publications (1)

Publication Number Publication Date
BRPI0511261A true BRPI0511261A (pt) 2007-11-27

Family

ID=34929115

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511261-3A BRPI0511261A (pt) 2004-05-18 2005-05-18 linhagem isolada de lactobacillus sp., uso de uma linhagem isolada de lactobacillus sp., e composição farmacêutica

Country Status (9)

Country Link
US (1) US20080253990A1 (pt)
EP (1) EP1751270A1 (pt)
JP (1) JP2007537741A (pt)
KR (1) KR20070026575A (pt)
CN (1) CN101052705A (pt)
AU (1) AU2005243441A1 (pt)
BR (1) BRPI0511261A (pt)
CA (1) CA2567106A1 (pt)
WO (1) WO2005111194A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852916B2 (en) 2010-01-22 2014-10-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with microorganisms
US8682619B2 (en) 2005-12-14 2014-03-25 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US8278094B2 (en) 2005-12-14 2012-10-02 The Invention Science Fund I, Llc Bone semi-permeable device
US8734823B2 (en) 2005-12-14 2014-05-27 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
RU2008147398A (ru) * 2006-05-02 2010-06-10 Актогеникс Н.В. (Be) Доставка пептидов, связанных с ожирением, через кишечник посредством микроорганизмов
DK3181682T3 (da) 2008-09-29 2021-07-05 Intrexon Actobiotics Nv Reduceret kolonisering af mikrober på slimhinden
EP2451467B1 (en) * 2010-01-14 2016-12-21 INSERM - Institut National de la Santé et de la Recherche Médicale Recombinant probiotic bacteria for the prevention and treatment of inflammatory bowel disease (ibd) and irritable bowel syndrome (ibs)
HUE038830T2 (hu) 2011-09-23 2018-11-28 Intrexon Actobiotics Nv Módosított gram-pozitív baktériumok és alkalmazásaik
JP6329903B2 (ja) 2011-09-23 2018-05-23 イントレクソン・アクトバイオテイクス・エヌブイＩｎｔｒｅｘｏｎ Ａｃｔｏｂｉｏｔｉｃｓ ＮＶ 改変されたグラム陽性菌及びその使用
WO2016124239A1 (en) * 2015-02-04 2016-08-11 Aurealis Oy Recombinant probiotic bacteria for use in the treatment of a skin dysfunction
EP3863655A4 (en) * 2018-10-09 2021-12-29 Second Genome, Inc. Lactococcus lactis expression system for delivering proteins efficacious for the treatment of epithelial barrier function disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1560935A2 (en) * 2002-11-15 2005-08-10 VIB vzw Self-containing lactobacillus strain

Also Published As

Publication number Publication date
EP1751270A1 (en) 2007-02-14
CA2567106A1 (en) 2005-11-24
CN101052705A (zh) 2007-10-10
US20080253990A1 (en) 2008-10-16
KR20070026575A (ko) 2007-03-08
WO2005111194A1 (en) 2005-11-24
JP2007537741A (ja) 2007-12-27
AU2005243441A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
BR112021022789A2 (pt) Métodos, sistemas e dispositivos para a seleção de pacientes para tl1a
BR112022002991A2 (pt) Compostos inibitórios de rip1 e métodos para preparação e uso dos mesmos
BRPI0511261A (pt) linhagem isolada de lactobacillus sp., uso de uma linhagem isolada de lactobacillus sp., e composição farmacêutica
BRPI0519242A2 (pt) uso derivados de 1-aminociclohexano para o tratamento de esclerose méltipla, instabilidade emocional e paralisia pseudobulbar
UY31073A1 (es) Inhibidores de la proteína activadora de la 5-lipoxigenasa (flap)
NO20084749L (no) Organiske forbindelser og deres anvendelser
CR9949A (es) Inhibidores de proteina activadora de la 5-lipoxigenasa (flap)
ECSP10010735A (es) Compuestos químicos 251
BR112012006144A2 (pt) novas individualidades de heparina e métodos de uso.
EP2494059A4 (en) USE OF METHYLSULFONYLMETHANE (MSM) TO MODULATE MICROBIAL ACTIVITY
BRPI0510999A (pt) dispositivo de eletrodesionização e métodos de uso
UY31067A1 (es) Inhibidores de proteina activadora de la 5-lipoxigenasa (flap)
BRPI1012219C1 (pt) produto, substrato, composição farmacêutica, usos de um produto, e de um peptídeo antimicrobiano, métodos para prevenir formação de biofilme em um ambiente, para tratar uma infecção microbiana por profilaxia ou terapia, e para tratar ou prevenir formação de biofilme em um ambiente, e, uso de uma cisteamina
BR112012027765A2 (pt) métodos, composições e kits para tratamento de distúrbios de mineralização da matriz.
BRPI0611717A2 (pt) composto, composiÇço farmacÊutica e uso do composto
BRPI1009842B8 (pt) uso de agonista de tlr9 e agonista de tlr2/6 na preparação de uma composição farmacêutica para tratamento, inibição ou atenuação de uma infecção microbiana, bem como composição farmaceuticamente aceitável compreendendo os referidos agonistas
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
UY30918A1 (es) Moduladores de lta4h y sus usos
BRPI0517286A (pt) modulação de rnai de rsv, piv e outras viroses respiratórias e empregos desta
WO2007146730A3 (en) Deacetylase inhibitor therapy
BRPI0917626A2 (pt) Método para modular atividade do fator 1 de transcrição do choque térmico (hsf1) em uma célula, método para aumentar ou diminuir a atividade de hsf1 em um indivíduo necessitando do mesmo método para tratar um paciente, método para identificar um agente que modula a atividade de hsf1 em uma célula, método para ativar a resposta ao choque térmico em uma célula ou em um paciente necessitando do mesmo e composição farmacêutica
BRPI0519690A2 (pt) composiÇÕes e mÉtodos para modular a expressço de genes usando oligonucleotÍdeos autoprotegidos
GB2453475A (en) Live vaccine strains of francisella
WO2018175749A3 (en) LRP1 BINDING AGENTS AND USES THEREOF
ZA202006077B (en) Human kynureninase enzymes and uses thereof

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired